Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 2
1994 1
1995 1
1996 4
1997 7
1998 5
1999 6
2000 5
2001 7
2002 5
2003 6
2004 5
2005 1
2006 6
2007 4
2008 5
2009 5
2010 4
2011 5
2012 2
2013 2
2014 7
2015 3
2016 7
2017 8
2018 7
2019 6
2020 2
2021 3
2022 3
2023 2
2024 4
2025 7
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Treatment Options for Visceral Leishmaniasis and HIV Coinfection.
Monge-Maillo B, López-Vélez R. Monge-Maillo B, et al. AIDS Rev. 2016 Jan-Mar;18(1):32-43. AIDS Rev. 2016. PMID: 26936761 Free article. Review.
One of the major challenges in the management of visceral leishmaniasis/HIV coinfection is developing an effective drug therapy that not only resolves the first episode of visceral leishmaniasis but also prevents relapse. However, scarce evidenc …
One of the major challenges in the management of visceral leishmaniasis/HIV coinfection is developing an effective drug …
Visceral leishmaniasis and HIV coinfection: current perspectives.
Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT. Lindoso JAL, et al. HIV AIDS (Auckl). 2018 Oct 15;10:193-201. doi: 10.2147/HIV.S143929. eCollection 2018. HIV AIDS (Auckl). 2018. PMID: 30410407 Free PMC article. Review.
Several outcomes are observed as a result of VL-HIV coinfection. Impacts are observed in immunopathogenesis, clinical manifestation, diagnosis, and therapeutic response. ...The combination of drugs and the use of secondary prophylaxis associated with highly a …
Several outcomes are observed as a result of VL-HIV coinfection. Impacts are observed in immunopathogenesis, clinical manifest …
Leishmaniasis.
Evans TG. Evans TG. Infect Dis Clin North Am. 1993 Sep;7(3):527-46. Infect Dis Clin North Am. 1993. PMID: 8254158 Review.
Leishmanial infections include three major clinical syndromes: visceral, cutaneous, and mucosal leishmaniasis. ...A practical approach to the clinical presentation, diagnostic measures, and some treatment options of these syndromes is presented in relation to …
Leishmanial infections include three major clinical syndromes: visceral, cutaneous, and mucosal leishmaniasis. ...A practical …
Treatment of leishmaniasis in HIV-positive patients.
Laguna F. Laguna F. Ann Trop Med Parasitol. 2003 Oct;97 Suppl 1:135-42. doi: 10.1179/000349803225002606. Ann Trop Med Parasitol. 2003. PMID: 14678640 Review.
Although, in southern Europe, there has been considerable experience in the treatment of visceral leishmaniasis (VL) in HIV-positive patients, the optimal therapy has yet to be established. ...Although the data available on secondary prophylaxis …
Although, in southern Europe, there has been considerable experience in the treatment of visceral leishmaniasis (VL) in HIV …
Visceral leishmaniasis and HIV coinfection in the Mediterranean region.
Monge-Maillo B, Norman FF, Cruz I, Alvar J, López-Vélez R. Monge-Maillo B, et al. PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3021. doi: 10.1371/journal.pntd.0003021. eCollection 2014 Aug. PLoS Negl Trop Dis. 2014. PMID: 25144380 Free PMC article. Review.
VL cases in this area account for 5%-6% of the global burden. Cases of Leishmania/HIV coinfection have been reported in the Mediterranean region, mainly in France, Italy, Portugal, and Spain. ...This article reviews the epidemiological, diagnostic, clinical, and the …
VL cases in this area account for 5%-6% of the global burden. Cases of Leishmania/HIV coinfection have been reported in the Me …
Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025.
Ambrosioni J, Levi LI, Alagaratnam J, Sempere A, Mastrangelo A, Paioni P, Mussini C, Marzolini C, Nielsen SD, Béguelin C, Welch S, Koval A, Mendao L, Bamford A, Calmy A, Guaraldi G, Oprea C, Martínez E, Rockstroh JK; EACS Governing Board. Ambrosioni J, et al. HIV Med. 2026 Jan;27(1):18-32. doi: 10.1111/hiv.70120. Epub 2025 Oct 15. HIV Med. 2026. PMID: 41088922 Free PMC article.
BACKGROUND: The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. KEY POINTS OF THE GUIDELINES UPDATE: The structure of the guidelines has been reorganized into two parts: Part I focuses …
BACKGROUND: The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects o …
Visceral Leishmaniasis and HIV coinfection in East Africa.
Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J. Diro E, et al. PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2869. doi: 10.1371/journal.pntd.0002869. eCollection 2014 Jun. PLoS Negl Trop Dis. 2014. PMID: 24968313 Free PMC article. Review.
Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload and first in VL-HIV coinfection rate. Because of the alteration in …
Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is s …
Immunocompromised travellers.
Wasilczuk K, Korzeniewski K. Wasilczuk K, et al. Int Marit Health. 2017;68(4):229-237. doi: 10.5603/IMH.2017.0041. Int Marit Health. 2017. PMID: 29297574 Free article. Review.
The article focuses on selected groups of immunocompromised travellers (ICTs), i.e., cancer patients, transplant patients receiving immunosuppressant agents, splenectomised patients and HIV-infected individuals. The most common infections and complications, includin …
The article focuses on selected groups of immunocompromised travellers (ICTs), i.e., cancer patients, transplant patients receiving immunosu …
Leishmaniasis.
Herwaldt BL. Herwaldt BL. Lancet. 1999 Oct 2;354(9185):1191-9. doi: 10.1016/S0140-6736(98)10178-2. Lancet. 1999. PMID: 10513726 Review.
Pentavalent antimony compounds have been the mainstay of antileishmanial therapy for half a century, but lipid formulations of amphotericin B (though expensive and administered parenterally) represent a major advance for treating visceral leishmaniasis. A pressing n …
Pentavalent antimony compounds have been the mainstay of antileishmanial therapy for half a century, but lipid formulations of amphot …
Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Marques N, Sá R, Coelho F, Oliveira J, Saraiva Da Cunha J, Meliço-Silvestre A. Marques N, et al. Scand J Infect Dis. 2008;40(6-7):523-6. doi: 10.1080/00365540701787800. Scand J Infect Dis. 2008. PMID: 18584541
Miltefosine is the first effective oral drug against visceral leishmaniasis. However, there are few data about its role against the increasing problem of HIV-associated visceral leishmaniasis. ...We report our experience with miltefosine in 5 HIV-infec …
Miltefosine is the first effective oral drug against visceral leishmaniasis. However, there are few data about its role against the i …
143 results